Home › Concept › Pediatric rollout 2000

Pediatric rollout from 2000

From 2000 onwards, transgender doctrine shifted from adults to children. The Dutch VUmc protocol — N=70, no control group, one center — was elevated to a global standard for pediatric gender care without any validation. No evidence base. Funding, yes, ideology, and a growing industry.

The "Dutch Protocol": an experiment on children

Peggy Cohen-Kettenis and colleagues published the "Dutch Protocol" in 2006 and 2011: triptorelin puberty blockers from Tanner stage 2, cross-sex hormones from age 16, and surgery from age 18. The cohort consisted of 70 carefully selected adolescents—virtually all boys with early-onset dysphoria. Based on this, the protocol was adopted worldwide: a methodologically absurdly large extrapolation from one small cohort to global application on a completely different population. See also the criticism of the VUmc protocol .

Crucially concealed: one participant died perioperatively from a complication of vaginoplasty. The study was continued. The Cass Review (2024) explicitly calls the research basis "not robust" — the mild phrasing for: this was never science on which medical decisions should be based.

International rollout: from VUmc to the world

The Tavistock Gender Identity Development Service (GIDS) in London adopted the protocol in 2011 via the Early Intervention Study. In the US, Boston Children's and Lurie Children's Hospital followed suit. Norman Spack had already started administering puberty blockers to minors under an experimental protocol in 2010. None of these clinics conducted controlled research into long-term effects — bone health, brain development, fertility, sexual function. It was a rollout, not research.

WPATH SOC7 (2011) and SOC8 (2022) codified the Dutch path as the "standard of care" — without an RCT, without a comparative study, and without an evidence tier. The WPATH Files (2024) show that internal reviews confirming the weak evidence base were suppressed. This is not an innocent mistake — this is institutional capture by a lobby. See also the US rollout and the European rollout .

The target group shifted — the protocol did not.

The original Dutch cohort consisted largely of boys with early-onset gender variance, often associated with later homosexuality (see desistance research : 60–90% of prepubertal children with dysphoria re-identify with their birth sex after puberty — usually as homosexual). In the 2010s, the population shifted radically: now predominantly teenage girls with late-onset — Littman's ROGD (2018). The Dutch protocol had not been developed or validated for this population.

The shift was ignored or dismissed by the affirmative lobby. The SBU (2022), NICE (2020), and COHERE (Finland) independently concluded that the Dutch protocol has no empirical justification in the modern population. Sweden, Finland, and the UK rolled back the pediatric rollout; the Netherlands stuck with its own export model . See also the social media explosion that drove the shift.

Frequently Asked Questions